



4C Biomed appoints Big Pharma Veteran as Chief Executive Officer

- ***Former Head of Oncology at AstraZeneca, Dr Alan Barge, appointed***
- ***Lead asset is an anti-4CB1, a first-in-class, fully human monoclonal antibody targeting HVEM***
- ***Programme to enter clinical development Q1 2027***

London and Israel – 18 August 2026: 4C Biomed, a biotechnology company developing novel immunotherapeutic monoclonal antibodies, announces the appointment of Dr Alan Barge, MA MB BS MRCP, to the role of Chief Executive Officer with immediate effect. He is taking on the CEO role from Eyal Greenberg, who has become the Company's Chief Development Officer and General Manager of R&D.

4C Biomed is an immune-oncology company focused on unlocking novel immune targets through its proprietary screening platform. Its lead programme is an anti-4CB1, a first-in-class, fully human monoclonal antibody targeting HVEM, a novel immune checkpoint which is highly expressed in malignant cancer cells across multiple cancers, including melanoma, renal, ovarian, colorectal, endometrial and hepatocellular carcinoma. Data shows that anti-4CB1 is active in tumours that have progressed on first-generation PD-1/L1 inhibitors, active in "cold" tumours unresponsive to PD-1/L1 therapy, and enhances the activity of those drugs in combination. The lead programme is due to enter the clinic in Q1 2027.

Dr Alan Barge said: *"This is an exciting time to be joining 4C Biomed as it is evolving into a clinical stage, fully integrated biotherapeutic company with its lead asset due to enter clinical development early next year. Having spent over 35 years bringing new oncology medicines through the clinic and onto market, I was attracted to 4C Biomed because of its innovative approach to extending immunotherapy to responding patients and delivering a potential solution for those patients where immunotherapy does not work. The team at 4C Biomed have a proven track record in cancer research and I'm looking forward to working with them."*

Dr Barge has worked extensively in the bio-pharmaceutical industry over the past 35 years. Most recently, he was CEO of Tilikum and SVP Oncology at Aslan Therapeutics, and before then he was Chief Medical Officer for Carrick Therapeutics. These appointments followed a 14 year career at AstraZeneca, where he rose from Worldwide Medical Director for Iressa®, to eventually become VP and Head of Oncology & Infection for AstraZeneca (AZ). As well as Iressa®, he was instrumental in developing a number of other ground-breaking cancer drugs, including Neupogen® and Lynparza®, the first effective treatment for BRCA-associated cancers. Before AZ, he was the European and Global Medical Director at Amgen. Currently, he is a Venture Partner of Delin Ventures

and a Non-Executive Director of AIM-listed, TheraCryf plc. Academically, Dr Barge trained in medicine at the Universities of Oxford and London, and completed his training in medical oncology in the United States.

Anthony Angel, Chair and Co-founder of 4C Biomed, added, *“4C Biomed is accelerating development of its lead asset, 4CB1 and we have therefore enhanced our team and appointed Alan Barge as CEO to accelerate our time to market. We are delighted that someone of his experience and expertise in the oncology space has agreed to join the Company. We believe we are taking a radical new approach to immuno-oncology that has potential across many different cancers and could make a significant difference to patients. We have a fantastic team already and we look forward to growing the Company further under Alan’s leadership.*

“I would also like to thank Eyal for his dedication and hard work to bring the Company to this stage of its development, as it plans for its first clinical trial. I’m very pleased that he is staying on to drive our business development strategy, where his deep knowledge of the Company and its science will be essential for building future strategic relationships with the biopharma industry.”

-Ends-

Notes to Editors

About 4C Biomed

4C Biomed is an immune-oncology company focused on unlocking novel immune targets through its proprietary screening platform. Its lead programme is an anti-4CB1, a first-in-class, fully human monoclonal antibody targeting HVEM, a novel immune checkpoint which is highly expressed in malignant cancer cells across multiple cancers, including melanoma, renal, ovarian, colorectal, endometrial and hepatocellular carcinoma. Data shows that anti-4CB1 is active in tumours that have progressed on first-generation PD-1/L1 inhibitors, active in “cold” tumours unresponsive to PD-1/L1 therapy, and enhances the activity of those drugs in combination.

The Company was spun out of Sheba Medical Center. The headquarters are located in London and its R&D is based in Israel. For more information, please visit the website: www.4CBiomed.com.

Contacts

4C Biomed

Dr Alan Barge

Email: info@4cbiomed.com

Vigo Consulting (media)

Melanie Toyne-Sewell

Rozi Morris

Tel: +44 (0)7890 022 814

Email: 4CBiomed@vigoconsulting.com